John joined Amgen in September 2016 at the Kendall Square facility in Cambridge, MA, with responsibility for Neuroscience Discovery Research, with teams spanning the Cambridge and Thousand Oaks locations. Previously John was VP and Head of the Neuroscience Innovative Medicine Unit at AstraZeneca leading discovery and early development efforts. Prior to joining AstraZeneca, John was Executive Director in the Neuroscience Research Unit at Pfizer with responsibility for the preclinical portfolios in Neurology and Psychiatry. John joined Pfizer as part of the Wyeth integration and at Wyeth held roles as head of Psychiatry and Acting head of Neuroscience. Trained as a neuropharmacologist, John’s current research interests include the role of proteostasis mechanisms and mitochondrial dysfunction in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and ALS, and on the emerging genetics of brain disorders. John is a scientific advisor to the ALS Association, Target-ALS, the frontotemporal dementia biomarkers SAB, the Weston Brain Institute of Canada and the National Institute for Neurological Disorders and Stroke for translational programs in neurological disorders.